Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · KRONOX LAB SCIENCES LTD · 6 November 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
KRONOX LAB SCIENCES LTD
NSE: KRONOX · BSE: 544187
NSE: KRONOX · BSE: 544187
Commodities › Chemicals › Chemicals & Petrochemicals › Specialty Chemicals
KRONOX LAB SCIENCES LTD
StateQ2 FY27 filed
Last close · 6 Nov 2026₹190.00
Market cap₹0.7k cr
TTM P/E · P/B · EV/EBITDA19.6 · 5.51 · 15.8
KRONOX LAB SCIENCES LTD is a Chemicals & Petrochemicals company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 90 | 100 | 101 |
| EBITDA (ex other income) | 28 | 33 | 34 |
| margin % | 31.5 | 33.1 | 33.9 |
| Owners' profit | 21 | 25 | 28 |
| EPS, as reported (₹) | 5.81 | 6.91 | 7.51 |
| ROE % · ROCE % | 32.2 · 43.1 | 28.1 · 34.9 | 23.8 · 31.9 |
| Debt / equity (x) | 0.00 | 0.00 | 0.01 |
| Cash from operations | 17 | 32 | 24 |
| Capex | (12) | (3) | (3) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · KRONOX LAB SCIENCES LTD · 6 November 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24 | 26 | 24 | 26 | 25 | 26 | 28 | 55 |
| Profit before tax | 9 | 8 | 8 | 9 | 9 | 11 | 10 | 19 |
| Net profit | 7 | 6 | 6 | 7 | 7 | 8 | 7 | 14 |
| EPS (₹) | 1.77 | 1.72 | 1.70 | 1.82 | 1.79 | 2.18 | 2.00 | 3.70 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,60,821 | 59.9 | 14.07 | 45.7 | 13.2 | 16.6 | 14.9 | 20.4 |
| SRF LTD | 73,182 | 31.9 | 4.78 | 22.8 | 8.3 | 8.6 | 13.4 | 19.3 |
| GUJARAT FLUOROCHEM LTD | 51,700 | 76.4 | 6.12 | 41.6 | 5.4 | 6.5 | 13.5 | 26.9 |
| NAVIN FLUORINE INT. LTD | 46,221 | 50.7 | 10.36 | 43.8 | 11.5 | 11.5 | 23.0 | 34.2 |
| DEEPAK NITRITE LTD | 20,937 | 19.7 | 3.21 | 22.7 | 11.4 | 12.6 | 12.6 | 20.4 |
| AETHER INDUSTRIES LIMITED | 20,745 | 83.0 | 8.00 | 58.3 | 5.0 | 5.9 | — | 31.8 |
| AARTI INDUSTRIES LTD | 16,004 | 21.4 | 2.55 | 17.4 | — | — | 13.0 | 13.1 |
| FINE ORGANIC IND. LTD. | 15,637 | 35.7 | 5.87 | 32.1 | 15.7 | 20.0 | 15.9 | 25.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 19.6 | 21.9 | 43 of 97 | 56% |
| P/B | 5.5 | 2.5 | 82 of 98 | 17% |
| Debt / Equity | 0.0 | 0.2 | 1 of 98 | 84% |
| EBITDA margin | 31.6 | 12.5 | 7 of 106 | 94% |
| Revenue growth | 116.3 | 28.1 | 11 of 97 | 90% |
| Profit growth | 105.8 | 49.9 | 24 of 94 | 75% |
| Market cap | 705 | 697 | 53 of 108 | 51% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · KRONOX LAB SCIENCES LTD · 6 November 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 6 Nov 2026 · CTL trustee discloses pledge over 14% of Kronox shares | ownership changes | high | — | — |
| 6 Nov 2026 · Indo Borax pledges 14% of Kronox shares for Rs 225 crore term loan | ownership changes | medium | — | — |
| 5 Nov 2026 · Open offer for Kronox Lab Sciences opens on November 6 | strategic transactions | medium | — | — |
| 5 Nov 2026 · Standalone September quarter revenue up 5.1%, profit after tax down 3.5%; control transferred | results | high | — | — |
| 5 Nov 2026 · Standalone Sep 2026 quarter: revenue up 5.1% year on year; EBITDA margin narrows; results approved | results | high | — | — |
| 3 Nov 2026 · Independent Directors publish views on 25.79% open offer | strategic transactions | high | — | — |
| 30 Oct 2026 · Board to review September 2026 quarterly and half-year results | results | low | — | — |
| 29 Oct 2026 · Indo Borax opens Rs 157.27 per share offer for up to 25.79% of Kronox | strategic transactions | high | — | — |
| 23 Oct 2026 · Share purchase agreement amended to remove seller lock-in and buyer priority | strategic transactions | high | — | — |
| 14 Oct 2026 · Board approves acquisition of chemical plant at Dahej SEZ from Axiom | strategic transactions | high | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in